Related references
Note: Only part of the references are listed.Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
Daniel J. Powell et al.
JOURNAL OF IMMUNOLOGY (2007)
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model
Kutlu G. Elpek et al.
JOURNAL OF IMMUNOLOGY (2007)
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
KL Knutson et al.
JOURNAL OF IMMUNOLOGY (2006)
Cutting edge:: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+ CD25+ T regulatory cells
Adam P. Kohm et al.
JOURNAL OF IMMUNOLOGY (2006)
Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4(+)CD25(+) regulatory T cells
SJ Prasad et al.
JOURNAL OF IMMUNOLOGY (2005)
Tumor-induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy
LM Peng et al.
JOURNAL OF IMMUNOLOGY (2002)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
IL-30 is required for regulatory T cells to mediate tolerance to alloantigens in vivo
M Hara et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
